PureTech Health (LON:PRTC) Trading Up 12.2% – Should You Buy?

PureTech Health plc (LON:PRTC) was up 12.2% during mid-day trading on Friday . The company traded as high as GBX 116 ($1.52) and last traded at GBX 115.61 ($1.51). Approximately 3,062,196 shares traded hands during trading, an increase of 184% from the average daily volume of 1,076,575 shares. The stock had previously closed at GBX 103 ($1.35).

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 455 ($5.96) price target on shares of PureTech Health in a report on Monday, December 16th.

PureTech Health Price Performance

The firm has a 50 day moving average price of GBX 135.24 and a two-hundred day moving average price of GBX 148.08. The company has a market cap of £354.45 million, a P/E ratio of -4.84 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.